Oncopeptides is a global biotech company committed to bringing innovation to patients with an unmet medical need and improving patient lives.
Our global Headquarters is based in Stockholm, and we also have a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.
Science driven culture
Oncopeptides is a R&D company with an inclusive organization that welcomes people with different backgrounds and perspectives. The drug development facility is an excellent example, with cutting edge drug development scientists representing many different nationalities.
Consistency in leadership
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions. Throughout the years the company has benefitted from consistency in executive management and Board of Directors. The company has continued to have close links to the researchers who initially developed Melflufen as well as to the founders of the company.
During more than a decade Oncopeptides has developed a wide network of collaborators and established partnerships with leading researchers and research institutions in Europe and the US, including the Harvard Medical School – Dana Farber Cancer Institute.